John Theurer Cancer Center at Hackensack University Medical Center 

Hackensack Meridian Health

Hackensack, NJ

Accepting patients

KarMMa-2

Phase 2 Clinical Trial Studying the Safety and Efficacy of bb2121 in Participants with Relapsed and Refractory Multiple Myeloma or Clinical High-Risk Multiple Myeloma
Learn more
  • CAR T Cell
  • BCMA
  • High Risk
  • Phase 2

Accepting patients

DREAMM12

A Study of Belantamab Mafodotin (GSK2857916) in Multiple Myeloma Participants With Normal and Varying Degrees of Impaired Renal Function
Learn more
  • Antibody Drug Conjugate (ADC)
  • BCMA
  • Phase 1

Accepting patients

CA057-003

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
Learn more
  • CELMoD
  • Phase 1/2

Not yet accepting

DREAMM13

A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Hepatic Function
Learn more
  • Antibody Drug Conjugate (ADC)
  • BCMA
  • Phase 1

Not yet accepting

MagnetisMM-7

Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Elranatamab VS Lenalidomide in Participants with Newly Diagnosed Multiple Myeloma Who Have Had an Autologous Stem Cell Transplant
Learn more
  • Bispecific Antibody
  • GPRC5D
  • Phase 3

Not yet accepting

CA088-1005

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component
Learn more
  • CAR T Cell
  • CELMoD
  • GPRC5D
  • Phase 1

Accepting patients

iMMAGINE-1

Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma
Learn more
  • CAR T Cell
  • BCMA
  • Phase 2

Accepting patients

Selinexor Combination Therapy

Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma
Learn more
  • SINE
  • High Risk
  • Phase 2

Not yet accepting

Carfilzomib Combination Therapy

Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment With Pomalidomide, Dexamethasone, and Carfilzomib (PdC) in Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
Learn more
  • Phase 2

Accepting patients

Selinexor

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
Learn more
  • SINE
  • Phase 2
3 hidden based on your filters. Show All

Filters

Diagnosis

Treatment History

BCMA Therapy

Advanced Filters

Trial Enrollment Status

Classifications

Targets

Trial Type

Phase